News

In this new oncology venture, VIB will become a shareholder alongside ThromboGenics, which will be the majority shareholder. ThromboGenics CEO Dr Patrik De Haes said: "The formation of

The deal will improve Hi-Tech’s Dietary Supplements and OTC product offering as well as expand its distribution through APN’s established platform. The transaction accelerates international growth strategy as

The Vancomycin 10g package is an addition to the company’s Vancomycin 5g pharmacy bulk package offering. The product is indicated to treat serious or severe infections caused by

The agency has issued the Prescription Drug User Fee Act (PDUFA) goal date in December 2015 for a decision on this NDA. The NDA seeks FDA approval of

Copanlisib is an intravenous pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against both PI3K-d and PI3K-a isoforms. The program now includes two new Phase III trials

Gencarois, the company’s investigational, pharmacologically unique beta-blocker and mild vasodilator, is indicated for heart failure patients with reduced left ventricular ejection fraction (HFREF). Currently, Gencaro is being evaluated

IV/IM meloxicam is a proprietary, Phase III-ready, long-acting COX-2 NSAID designed for the management of moderate to severe acute pain. As part of the deal, Recro paid Alkermes

As part of the deal, Boehringer is responsible for the global development and commercialization of the new inhibitors, while Hydra will receive an undisclosed upfront payment, additional research

In February 2015, the US Food and Drug Administration (FDA) granted approval for Liletta based on the largest hormonal IUD trial conducted in the US, A Comprehensive Contraceptive